# Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

> **NCT02265952** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** REGN1500 250 mg SC/15 mg/kg IV/450 mg SC

## Key facts

- **NCT ID:** NCT02265952
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-04
- **Primary completion:** 2016-11-21
- **Final completion:** 2018-07-23
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02265952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02265952, "Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02265952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*